Enveda Reports Positive Phase 1 Results for ENV-308, an Oral Therapy Designed to Support Long-Term Metabolic Health
As the use of GLP-1 medications continues to expand among adults in the United States, growing attention is being directed toward a major challenge in obesity and metabolic care: maintaining weight loss and metabolic improvements over the long term. While GLP-1 therapies have transformed the treatment landscape for obesity and related metabolic conditions, many people who use these medicines primarily for weight management eventually discontinue treatment, raising questions about how to sustain the benefits after therapy ends.
Against this backdrop, Enveda has announced positive Phase 1 clinical results for ENV-308, an investigational once-daily oral medicine designed to replicate some of the biological effects of Lac-Phe, a naturally occurring molecule associated with exercise and nutrient sensing. The company believes ENV-308 could represent a new approach to supporting long-term metabolic health and potentially helping people maintain benefits achieved through weight-loss interventions.
Enveda is a biotechnology company using artificial intelligence and natural-product chemistry to discover new medicines. ENV-308 was identified using the company’s proprietary PRISM platform, an artificial intelligence model designed to uncover biologically active molecules found in nature and within biological systems.
The Phase 1 trial evaluated ENV-308 in healthy adult volunteers, with a primary focus on safety, tolerability, and the way the investigational drug behaves in the body. According to Enveda, the study generated encouraging findings across the tested dose range and provided the company with sufficient confidence to move the program toward further clinical development.
Growing Need for Sustainable Weight Management
GLP-1 medications have become an important component of modern obesity and metabolic disease management. Their ability to reduce appetite, promote weight loss, and improve markers such as blood glucose has resulted in widespread adoption.
However, long-term treatment remains a challenge for many patients. Enveda cited estimates indicating that approximately one in eight U.S. adults use GLP-1 medications, while a substantial proportion of individuals who primarily take these medicines for weight loss discontinue them within the first year.
A recent meta-analysis from the University of Oxford further highlighted the difficulty of maintaining the benefits of GLP-1 therapy after treatment cessation. According to the analysis cited by Enveda, many of the improvements in body weight and metabolic measures, including HbA1c, may diminish after people stop taking GLP-1 medications. The analysis also suggested that weight regain following discontinuation can occur more rapidly than weight regain after some non-drug weight-management programs.
Researchers are increasingly examining whether repeated cycles of weight loss and weight regain, sometimes described as “yo-yo” weight cycling, could have implications for cardiometabolic health. These concerns underscore the need for approaches that can help people preserve improvements in weight and metabolism rather than requiring indefinite reliance on therapies that some patients may find difficult to tolerate or continue.
Enveda is positioning ENV-308 as a potential solution to this gap between achieving weight loss and maintaining the associated health benefits over time.
Inspired by the Biology of Exercise
ENV-308 was discovered through Enveda’s PRISM platform, which the company developed to analyze natural and biological chemistry and identify molecules with potential therapeutic applications.
The investigational therapy is designed to mimic Lac-Phe, a molecule that has attracted significant scientific interest since researchers identified its role in exercise biology. Lac-Phe is produced by the body during intense physical activity and has also been linked to nutrient sensing following meals.
Research led by Stanford scientist Jonathan Long and colleagues helped characterize Lac-Phe and its role in exercise-associated metabolic effects. Preclinical research has indicated that Lac-Phe can suppress appetite and reduce obesity in animal models, providing insight into how exercise may influence metabolism through chemical signals produced by the body.
Despite its biological activity, naturally occurring Lac-Phe has limitations that prevent it from functioning effectively as a conventional medicine. The molecule is cleared from the body too quickly to provide the sustained exposure typically required for a therapeutic product.
Enveda therefore engineered ENV-308 to reproduce relevant Lac-Phe activity while providing properties intended to support administration as a daily oral medication.
Viswa Colluru, Ph.D., founder and CEO of Enveda, said many of the beneficial effects associated with exercise may be connected to chemical messengers released by the body. According to Colluru, ENV-308 represents an effort to translate some of the chemistry associated with exercise into a convenient daily treatment that could potentially complement people’s long-term health routines.
Positive Safety and Tolerability Findings
The Phase 1 study has enrolled 88 healthy adult volunteers to date. The trial was primarily designed to evaluate the safety and tolerability of ENV-308, as well as pharmacokinetic characteristics and how the drug behaves in the human body.
According to Enveda, participants tolerated ENV-308 well across the full range of doses evaluated in the study. One of the most notable findings was the reported gastrointestinal safety profile.
Gastrointestinal adverse effects, including nausea and vomiting, are among the side effects frequently associated with GLP-1 medications and can contribute to treatment discontinuation. Enveda said that no serious adverse events, treatment discontinuations, or dose interruptions were reported in the Phase 1 trial of ENV-308.
Although these early findings do not establish the drug’s effectiveness for weight loss or metabolic disease, the reported tolerability profile could be important as the company advances the program into studies involving people with obesity and other metabolic conditions.
ENV-308 and Leptin Biology
The Phase 1 study also generated findings involving leptin, an important hormone produced by fat cells that helps regulate appetite and energy balance.
Leptin communicates with the brain regarding the amount of energy stored in the body. In people living with obesity, circulating leptin levels are often chronically elevated. Despite these elevated levels, the brain may become less responsive to leptin, a phenomenon commonly referred to as leptin resistance.
Preclinical studies of ENV-308 had previously demonstrated rapid reductions in leptin levels. Enveda said these findings could potentially be consistent with changes in leptin responsiveness or sensitivity.
The company reported that reductions in circulating leptin were also observed in the Phase 1 clinical trial. The most pronounced reductions occurred among participants who had the highest baseline leptin levels relative to their sex.
Enveda plans to conduct additional research to better understand how ENV-308 influences leptin biology and whether changes in leptin levels translate into meaningful improvements in appetite regulation, body weight, or metabolic health.
Potential Role Alongside GLP-1 Treatments
Preclinical research has also raised the possibility that ENV-308 could be used in combination with GLP-1 therapies.
In animal studies, Enveda reported that treatment with ENV-308 helped maintain weight loss after a previous weight-loss intervention was withdrawn, without the rebound observed in control settings. The company also reported that ENV-308 appeared to have additive effects when used with GLP-1 therapies.
These findings raise the possibility that ENV-308 could eventually be used as part of a treatment strategy designed to maintain the benefits achieved through other weight-loss interventions. Preclinical data have also suggested the possibility that ENV-308 could allow GLP-1 medicines to be administered less frequently or potentially help address certain tolerability concerns.
However, these observations have only been demonstrated in animal studies and have not yet been established in humans. Enveda plans to evaluate these hypotheses in future clinical trials.
Experts Highlight Potential of a New Metabolic Approach
Jonathan Long, PhD, associate professor of pathology and Institute Scholar at Stanford ChEM-H, and a leading researcher in exercise metabolism, described the emerging science surrounding Lac-Phe as an exciting area of research.
According to Long, preclinical evidence suggests that Lac-Phe may influence several aspects of metabolic, neurological, and inflammatory health. He said the possibility of reproducing some of these effects through an oral medicine such as ENV-308 could represent an important scientific development if confirmed in clinical studies.
Nadeem Sarwar, Global Head of Metabolic Strategy & Disease Prevention at Enveda, also emphasized the potential of combining AI-driven drug discovery with insights from exercise biology. He said the Phase 1 tolerability results, together with the observed effects on leptin, provide encouragement for continued development of ENV-308 as a potential new class of therapy focused on long-term metabolic health.
Phase 2 Development Planned
Because the Phase 1 study enrolled healthy volunteers, it was not designed to determine whether ENV-308 causes weight loss or produces improvements in metabolic health. As a result, the current results should not be interpreted as evidence that ENV-308 is an effective weight-loss treatment.
Future studies will evaluate more clinically relevant endpoints, including body weight, body composition, and metabolic biomarkers. Enveda is particularly interested in determining whether ENV-308 can help maintain weight loss and other metabolic improvements after patients discontinue GLP-1 medications.
The company plans to evaluate this potential in a Phase 2 clinical trial, focusing on individuals who have previously achieved weight loss through GLP-1 treatment and subsequently discontinued therapy.
Naveed Sattar, Professor of Metabolic Medicine at the University of Glasgow and Chair of the UK Obesity Healthcare Goals Programme, said that recent advances in weight-loss medicines have created important new treatment options for people with obesity, but maintaining long-term protection against cardiometabolic disease remains a significant unmet need.
According to Sattar, therapies capable of sustaining metabolic improvements could complement existing approaches and potentially address an important limitation in current obesity treatment.
Broader Development Opportunities
Enveda is also investigating whether the biological effects associated with ENV-308 could have applications beyond obesity and weight management. The company is evaluating the compound in additional areas where exercise and metabolic signaling may play an important role.
Potential indications under consideration include migraine, inflammatory bowel disease, and polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome.
The expansion of ENV-308 into these areas reflects Enveda’s broader interest in understanding how naturally occurring molecules and biological pathways can be translated into new medicines.
For now, the company’s immediate priority is to advance ENV-308 into further clinical testing and determine whether the promising safety and pharmacological findings observed in Phase 1 can translate into meaningful benefits for patients.
If future studies confirm its ability to support weight maintenance, metabolic health, and potentially the benefits achieved through GLP-1 treatment, ENV-308 could emerge as a complementary approach to the rapidly evolving obesity treatment landscape. The next phase of clinical development will be critical in determining whether the molecule can move beyond its encouraging early-stage findings and demonstrate clinically meaningful benefits in people living with obesity and related metabolic conditions.
About ENV-308
ENV-308 is an investigational, daily oral small molecule inspired by the chemistry and biology of exercise and is in development for metabolic and other diseases. The therapy was discovered using Enveda’s proprietary AI-enabled platform and engineered to mimic the therapeutic effects of Lac-Phe, a hormone released during intense exercise. In preclinical studies, ENV-308 demonstrated preservation of lean muscle mass during weight loss, durable weight maintenance, favorable gastrointestinal tolerability, improved GLP-1 dosing frequency and tolerability, and broad metabolic and other benefits. ENV-308 is being developed as a chronic therapy to support long-term metabolic health, including weight and metabolic maintenance following GLP-1 treatment.
About Enveda
Enveda is a biotechnology company that learns from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, the vast majority of which have never been explored by science, creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s most pressing medical needs. For more information, visit enveda.com.